Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 5/20 | 0.72 |
| ▸ | DRD2 | P14416 | 3/20 | 0.58 |
| ▸ | HTR1A | P08908 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | DRD3 | P35462 | 2/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1711188 | 0.87 | DRD4 (0.77) | DRD4DRD2DRD3SIGMAR1KDM4E | |
| SCHEMBL5986956 | 0.87 | DRD4 (0.77) | DRD4DRD2HTR1ACYP2D6DRD3 | |
| Dopamine SCHEMBL6032806 | 0.85 | DRD4 (0.60) | DRD4DRD2HTR1ACYP2D6DRD3 | |
| SCHEMBL6031812 | 0.84 | DRD4 (1.00) | DRD4DRD2HTR1ADRD3SIGMAR1 | |
| SCHEMBL28155449 | 0.84 | DRD4 (0.72) | DRD4DRD2HTR1ADRD3SIGMAR1 | |
| SCHEMBL4649494 | 0.81 | DRD4 (0.87) | DRD4DRD2DRD3SIGMAR1KDM4E | |
| SCHEMBL22532699 | 0.81 | DRD4 (0.79) | DRD4DRD2HTR1ADRD3SIGMAR1 | |
| SCHEMBL12861757 | 0.81 | DRD4 (0.79) | DRD4DRD2HTR1ADRD3SIGMAR1 | |
| SCHEMBL13959204 | 0.80 | HTR1A (0.71) | DRD4DRD2HTR1ASIGMAR1ADRA1D | |
| SCHEMBL3242189 | 0.80 | DRD4 (0.77) | DRD4DRD2HTR1ADRD3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1678591-A | Novel carboxamide compounds having MCH-antagonistic action, pharmaceutical preparations comprising said compounds and process for their preparation | BOEHRINGER INGELHEIM INT (DE) | 2005-10-05 | — | — | CN | disclosed |
| EP-1534689-A1 | NOVEL CARBOXAMIDE COMPOUNDS HAVING AN MCH-ANTAGONISTIC EFFECT, MEDICAMENTS CONTAINING SAID COMPOUNDS, AND METHODS FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-06-01 | — | — | EP | disclosed |
| US-20040242572-A1 | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-12-02 | — | — | US | disclosed |
| WO-2004024702-A1 | NOVEL CARBOXAMIDE COMPOUNDS HAVING AN MCH-ANTAGONISTIC EFFECT, MEDICAMENTS CONTAINING SAID COMPOUNDS, AND METHODS FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242572-A1 | New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture | MCHR2, MCHR1, NPY1R | DRD4 416/4885DRD2 286/4885HTR1A 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.